Menu Search
Equities

Egetis Therapeutics AB (publ)

0ABW:LSE

Egetis Therapeutics AB (publ)

Actions
  • Price (SEK)5.32
  • Today's Change-0.28 / -5.00%
  • Shares traded1.56k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 15:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

  • Revenue in SEK (TTM)79.20m
  • Net income in SEK-295.80m
  • Incorporated2006
  • Employees33.00
  • Location
    Egetis Therapeutics AB (publ)Klara Norra Kyrkogata 26STOCKHOLM 111 22SwedenSWE
  • Phone+46 86797210
  • Fax+46 86635725
  • Websitehttps://www.egetis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.